JAFRAL Phage Summit 2026

-

JAFRAL Phage Summit 2026

19–21 May 2026 | Ljubljana, Slovenia

As antimicrobial resistance (AMR) accelerates and antibiotics lose ground, the world urgently needs new therapeutic solutions that are both effective and patient‑centred. Bacteriophages are emerging as one of the most promising tools we have.

What the phage field needs most today is deeper global connection, stronger collaboration, and a shared roadmap for turning scientific progress into real‑world therapies.

And that is exactly what the JAFRAL Phage Summit 2026 will deliver.

A Global Meeting Shaping the Future of Phage Therapy

From clinicians, pharmacists and infectious disease specialists to biotech innovators, regulatory authorities, researchers and industry leaders, this summit brings together every key stakeholder driving the next era of phage therapy.

Over three intensive days, participants will explore new developments, share clinical experiences, and accelerate the translation of phage science into safe, effective and accessible therapies for patients worldwide.

This is more than a conference — it’s a collective step toward redefining how we treat bacterial infections.

 

What You Can Expect

Participants will have the opportunity to:

·       Learn from real‑world clinical experiences and compassionate‑use cases

·       Gain insights into active clinical trials and emerging outcomes

·       Join cross‑disciplinary discussions that break silos and spark new collaborations

·        Discover how innovations are moving from lab to clinic

·       Connect with an international network dedicated to advancing patient care

Whether you’re a seasoned expert or just entering the field, you’ll find valuable opportunities to learn, collaborate and contribute to meaningful progress.

 

Who Should Attend

This summit is ideal for:

  • Pharma & biotech professionals
  • Medical doctors, clinicians & infectious disease specialists
  • Regulatory authorities & policymakers
  • Hospital, clinical & community pharmacists
  • Researchers & translational scientists
  • Healthcare organizations & hospital networks
  • Manufacturers & industry partners
  • Academic, public health & AMR educators
  • Students and early‑career professionals eager to join the field

Whether you’re a seasoned expert or just entering the field, you’ll find valuable opportunities to learn, collaborate and contribute to meaningful progress.

 

Keynote Speakers & Expert Line‑up

The summit features leaders from top global institutions, across three themed days:

Day 1 – AMR Strategy, Global Policy & Phage Therapy

  • Dr. Rob Lavigne, KU Leuven
  • Dr. Jochem Spoor, Erasmus Medical Center
  • Dr. Tobi Nagel, Phages for Global Health
  • Dr. Zuzanna Kazmierczak, Hirszfeld Institute
  • Mr. Anthony Rodiadis, European Commission
  • Mr. Pietro Erba, European Commission
  • Ms. Tine Rikke Jørgensen, Former WHO AMR Innovation / The Globe Institute

 

Day 2 – Clinical Evidence: Trials, Results & Impact

·       Dr. Christian Grøndahl, SNIPR Biome

  • Dr. Radu Botgros, EMA
  • Dr. Alexander Sulakvelidze, Intralytix
  • Dr. Shawna McCallin, Balgrist University Hospital
  • Dr. Minmin Yen, PhagePro
  • Dr. Carmen Coxon, MHRA
  • Ms. Amanda Burkardt, Phiogen Pharma
  • Dr. Sofia Corte‑Real, Technophage

Day 3 – From Compassionate Use to Practice: Real‑World Outcomes & Patient Impact

  • Dr. Saima Aslam, UC San Diego Health
  • Ms. Karen Northshield, phage therapy patient
  • Dr. Anja Düchtling, BfArM
  • Dr. Mark Sutton, UK Health Security Agency
  • Dr. Silvia Würstle, Frankfurt University Hospital
  • Dr. Andrej Trampuž, Centre for Immunology and Infection Control
  • Dr. Jean‑Paul Pirnay, Queen Astrid Military Hospital
  • Dr. Kārlis Rācenis, Rīga Stradiņš University
  • Dr. Steffen Lanwald, BG Klinikum Bergmannstrost Halle

 

Program Highlights

Day 1 – Global Infectious Disease Landscape & Phage Therapy

  • The global AMR challenge
  • EU policy, regulation & innovation
  • Insights from infectious disease specialists
  • Phage therapy as a global health solution

Day 2 – Clinical Trials & Current Results

  • Latest outcomes from completed trials
  • Updates from ongoing studies
  • Regulatory guidance shaping clinical development
  • Breakthroughs from biotech innovators

Day 3 – Compassionate Use & Magistral Preparations

  • Practical approaches to personalised phage therapy
  • Case studies & patient journeys
  • Compassionate‑use regulations
  • Real‑world hospital experiences

 

Why This Summit Matters?

2026 marks a turning point for phage therapy:

  • Growing clinical evidence
  • Increasing regulatory engagement
  • Rising demand from hospitals and healthcare systems
  • Expanding biotech and pharma investment
  • A global push to confront AMR collaboratively

The JAFRAL Phage Summit 2026 is where these forces converge — creating momentum toward a world where phage therapy becomes an accessible, routine option for patients who need it most.

Poster Submissions

We are also pleased to announce that poster submissions are now open. We welcome contributions from researchers, students, clinicians, and professionals wishing to present their work to the global phage community.

If you are developing a project, case study, or innovative concept in the field, we encourage you to submit your work for consideration.

Additional details and submission guidelines are available on our website: Jafral

 

For the latest news about the conference, registration prices, speaker announcements, or any other updates, you can:

Learn more on: https://www.jafral.com/phage-summit-2026

Follow us on: https://www.linkedin.com/showcase/jafral-phage-summit-2026/

 

Comments

Post a Comment

Popular posts from this blog

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

-
Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more